Do analysts rate FBLG or AEON?

FibroBiologics presently has a consensus price target of $74.00, suggesting a potential upside of 8,680.26%. Given FibroBiologics' higher probable upside, equities analysts plainly believe FibroBiologics is more favorable than AEON Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has preferable earnings & valuation, FBLG or AEON?

FibroBiologics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FibroBiologics N/A N/A -$18.65M -$6.93 N/A AEON Biopharma N/A N/A -$36.63M -$5.00 N/A

Is FBLG or AEON more profitable?

AEON Biopharma's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -767.07% -195.56% AEON Biopharma N/A N/A -994.63%

Does the media favor FBLG or AEON?

In the previous week, FibroBiologics and FibroBiologics both had 3 articles in the media. FibroBiologics' average media sentiment score of 0.88 beat AEON Biopharma's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AEON Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALLR or FBLG more profitable?

Allarity Therapeutics' return on equity of -109.94% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% FibroBiologics N/A -767.07% -195.56%

Does the media favor ALLR or FBLG?

In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 3 articles in the media. Allarity Therapeutics' average media sentiment score of 0.96 beat FibroBiologics' score of 0.88 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, AKTX or FBLG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A FibroBiologics N/A N/A -$18.65M -$6.93 N/A

Is AKTX or FBLG more profitable?

Akari Therapeutics' return on equity of -123.29% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -123.29% -63.01% FibroBiologics N/A -767.07% -195.56%

Does the media refer more to AKTX or FBLG?

In the previous week, Akari Therapeutics and Akari Therapeutics both had 3 articles in the media. Akari Therapeutics' average media sentiment score of 1.29 beat FibroBiologics' score of 0.88 indicating that Akari Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HOWL or FBLG more profitable?

Werewolf Therapeutics' return on equity of -208.23% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% FibroBiologics N/A -767.07% -195.56%

Does the media favor HOWL or FBLG?

In the previous week, Werewolf Therapeutics had 1 more articles in the media than FibroBiologics. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 3 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.88 beat Werewolf Therapeutics' score of 0.28 indicating that FibroBiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend FBLG or GTBP?

FibroBiologics currently has a consensus price target of $74.00, suggesting a potential upside of 8,680.26%. Given FibroBiologics' stronger consensus rating and higher possible upside, equities research analysts plainly believe FibroBiologics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, FBLG or GTBP?

FibroBiologics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FibroBiologics N/A N/A -$18.65M -$6.93 N/A GT Biopharma N/A N/A -$28.35M -$6.33 N/A

Is FBLG or GTBP more profitable?

GT Biopharma's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -767.07% -195.56% GT Biopharma N/A N/A -102.03%

FibroBiologics (FBLG) Competitors

$0.84 -0.01 (-1.03%)

Closing price 07/15/2026 04:00 PM Eastern

Extended Trading

$0.86 +0.02 (+1.92%)

As of 07/15/2026 07:03 PM Eastern

Compare

FBLG vs. AEON, ALLR, AKTX, HOWL, and GTBP

Should you buy FibroBiologics stock or one of its competitors? MarketBeat compares FibroBiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FibroBiologics include AEON Biopharma (AEON), Allarity Therapeutics (ALLR), Akari Therapeutics (AKTX), Werewolf Therapeutics (HOWL), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical products" industry.

How does FibroBiologics compare to AEON Biopharma?

FibroBiologics (NASDAQ:FBLG) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

AEON Biopharma's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
AEON Biopharma	N/A	N/A	-994.63%

FibroBiologics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A

22.8% of AEON Biopharma shares are owned by institutional investors. 9.3% of FibroBiologics shares are owned by insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

FibroBiologics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

FibroBiologics presently has a consensus price target of $74.00, suggesting a potential upside of 8,680.26%. Given FibroBiologics' higher probable upside, equities analysts plainly believe FibroBiologics is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, FibroBiologics and FibroBiologics both had 3 articles in the media. FibroBiologics' average media sentiment score of 0.88 beat AEON Biopharma's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AEON Biopharma beats FibroBiologics on 7 of the 12 factors compared between the two stocks.

How does FibroBiologics compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Allarity Therapeutics has higher revenue and earnings than FibroBiologics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	58.67	-$11.23M	-$0.72	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

Allarity Therapeutics presently has a consensus price target of $10.25, suggesting a potential upside of 768.64%. FibroBiologics has a consensus price target of $74.00, suggesting a potential upside of 8,680.26%. Given FibroBiologics' higher possible upside, analysts clearly believe FibroBiologics is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 3 articles in the media. Allarity Therapeutics' average media sentiment score of 0.96 beat FibroBiologics' score of 0.88 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allarity Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

11.5% of Allarity Therapeutics shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by insiders. Comparatively, 9.3% of FibroBiologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Allarity Therapeutics' return on equity of -109.94% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
FibroBiologics	N/A	-767.07%	-195.56%

Summary

Allarity Therapeutics beats FibroBiologics on 7 of the 11 factors compared between the two stocks.

How does FibroBiologics compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

In the previous week, Akari Therapeutics and Akari Therapeutics both had 3 articles in the media. Akari Therapeutics' average media sentiment score of 1.29 beat FibroBiologics' score of 0.88 indicating that Akari Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akari Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

5.1% of Akari Therapeutics shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by insiders. Comparatively, 9.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Akari Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Akari Therapeutics presently has a consensus target price of $89.00, indicating a potential upside of 637.37%. FibroBiologics has a consensus target price of $74.00, indicating a potential upside of 8,680.26%. Given FibroBiologics' higher probable upside, analysts plainly believe FibroBiologics is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Akari Therapeutics' return on equity of -123.29% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
FibroBiologics	N/A	-767.07%	-195.56%

Summary

Akari Therapeutics beats FibroBiologics on 9 of the 10 factors compared between the two stocks.

How does FibroBiologics compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Werewolf Therapeutics' return on equity of -208.23% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
FibroBiologics	N/A	-767.07%	-195.56%

Werewolf Therapeutics currently has a consensus price target of $3.75, suggesting a potential upside of 1,004.57%. FibroBiologics has a consensus price target of $74.00, suggesting a potential upside of 8,680.26%. Given FibroBiologics' higher probable upside, analysts clearly believe FibroBiologics is more favorable than Werewolf Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

64.8% of Werewolf Therapeutics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 9.3% of FibroBiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

FibroBiologics has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	8.78	-$60.82M	-$1.24	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

In the previous week, Werewolf Therapeutics had 1 more articles in the media than FibroBiologics. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 3 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.88 beat Werewolf Therapeutics' score of 0.28 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Werewolf Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Summary

Werewolf Therapeutics beats FibroBiologics on 9 of the 14 factors compared between the two stocks.

How does FibroBiologics compare to GT Biopharma?

FibroBiologics (NASDAQ:FBLG) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

8.2% of GT Biopharma shares are held by institutional investors. 9.3% of FibroBiologics shares are held by company insiders. Comparatively, 1.2% of GT Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

FibroBiologics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

In the previous week, FibroBiologics had 2 more articles in the media than GT Biopharma. MarketBeat recorded 3 mentions for FibroBiologics and 1 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.91 beat FibroBiologics' score of 0.88 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
FibroBiologics	Positive
GT Biopharma	Very Positive

FibroBiologics currently has a consensus price target of $74.00, suggesting a potential upside of 8,680.26%. Given FibroBiologics' stronger consensus rating and higher possible upside, equities research analysts plainly believe FibroBiologics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

FibroBiologics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

GT Biopharma's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
GT Biopharma	N/A	N/A	-102.03%

Summary

FibroBiologics beats GT Biopharma on 7 of the 13 factors compared between the two stocks.

Get FibroBiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBLG vs. The Competition

Export

Metric	FibroBiologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.18M	$3.65B	$6.78B	$12.56B
Dividend Yield	N/A	2.22%	2.68%	9.46%
P/E Ratio	-0.12	21.32	27.12	24.35
Price / Sales	N/A	178.06	487.91	76.72
Price / Cash	N/A	143.89	48.63	60.00
Price / Book	0.46	8.56	10.82	6.31
Net Income	-$18.65M	$23.88M	$3.59B	$331.55M
7 Day Performance	3.18%	-2.32%	-1.21%	0.15%
1 Month Performance	-5.62%	6.47%	3.13%	-0.68%
1 Year Performance	-93.95%	53.33%	29.12%	20.73%

FibroBiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBLG FibroBiologics	2.6123 of 5 stars	$0.84 -1.0%	$74.00 +8,680.3%	-94.0%	$5.18M	N/A	N/A	10	Gap Down
AEON AEON Biopharma	0.749 of 5 stars	$0.71 -3.0%	N/A	-62.5%	$17.92M	N/A	3.93	5	News Coverage Gap Down
ALLR Allarity Therapeutics	2.4964 of 5 stars	$1.10 -8.3%	$10.25 +831.8%	+16.8%	$17.50M	$320K	N/A	10	Short Interest Decrease
AKTX Akari Therapeutics	3.0677 of 5 stars	$15.12 +38.7%	$89.00 +488.6%	-72.3%	$17.24M	N/A	N/A	9	Positive News Short Interest Decrease Gap Down
HOWL Werewolf Therapeutics	3.4624 of 5 stars	$0.34 +7.2%	$3.75 +993.3%	-74.1%	$16.67M	$1.88M	N/A	40	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBLG) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FibroBiologics (FBLG) Competitors

FBLG vs. AEON, ALLR, AKTX, HOWL, and GTBP

How does FibroBiologics compare to AEON Biopharma?

Summary

How does FibroBiologics compare to Allarity Therapeutics?

Summary

How does FibroBiologics compare to Akari Therapeutics?

Summary

How does FibroBiologics compare to Werewolf Therapeutics?

Summary

How does FibroBiologics compare to GT Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FibroBiologics (FBLG) Competitors

FBLG vs. AEON, ALLR, AKTX, HOWL, and GTBP

How does FibroBiologics compare to AEON Biopharma?

Is FBLG or AEON more profitable?

Which has preferable earnings & valuation, FBLG or AEON?

Do insiders & institutionals have more ownership in FBLG or AEON?

Which has more volatility & risk, FBLG or AEON?

Do analysts rate FBLG or AEON?

Does the media favor FBLG or AEON?

Summary

How does FibroBiologics compare to Allarity Therapeutics?

Which has stronger earnings & valuation, ALLR or FBLG?

Do analysts prefer ALLR or FBLG?

Does the media favor ALLR or FBLG?

Which has more volatility & risk, ALLR or FBLG?

Do insiders and institutionals have more ownership in ALLR or FBLG?

Is ALLR or FBLG more profitable?

Summary

How does FibroBiologics compare to Akari Therapeutics?

Which has better valuation & earnings, AKTX or FBLG?

Does the media refer more to AKTX or FBLG?

Do institutionals and insiders have more ownership in AKTX or FBLG?

Which has more risk & volatility, AKTX or FBLG?

Do analysts rate AKTX or FBLG?

Is AKTX or FBLG more profitable?

Summary

How does FibroBiologics compare to Werewolf Therapeutics?

Is HOWL or FBLG more profitable?

Do analysts rate HOWL or FBLG?

Do insiders & institutionals hold more shares of HOWL or FBLG?

Which has better valuation and earnings, HOWL or FBLG?

Does the media favor HOWL or FBLG?

Which has more volatility and risk, HOWL or FBLG?

Summary

How does FibroBiologics compare to GT Biopharma?

Do institutionals and insiders hold more shares of FBLG or GTBP?

Which has more volatility and risk, FBLG or GTBP?

Does the media refer more to FBLG or GTBP?

Do analysts recommend FBLG or GTBP?

Which has stronger valuation and earnings, FBLG or GTBP?

Is FBLG or GTBP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools